c4c European network
The aim of the Collaborative Network for European Clinical Trials for Children (c4c) project is to improve treatment for children by setting up a clinical research network in Europe. It brings together 43 academic and industrial partners (universities, hospitals, national research organizations, patient associations, pharmaceutical companies) over 50 third parties and nearly 500 affiliated partners from 19 European countries. It is an IMI2 project (Innovative Medicine Initiative) created equally by academia and industry. (http://conect4children.org)
Europe must become more competitive for the benefit of children by using all available expertise. By federating the existing structures and sharing the same objectives, the European network will be stronger. This network should help to promote high quality trials in a reasonable (and reduced) timeframe, including for rare diseases.
Regardless of the research project, it can easily turn to this one-stop shop, c4c, to be able to develop treatments in children more easily, faster and with better results.
It is a vast and innovative project, which already involves children and their families through expert children’s groups (YPAG). The clinical trials will be organized and realized by a global approach by bringing together, from the beginning of the project: the researchers, the industrialists, the children and their parents and established contacts within the regulatory authorities..
The national infrastructure F-CRIN is a label of quality and excellence. It aims to improve the performance of French clinical research. Created in 2013 (2012 ?), F-CRIN labels and supports 12 thematic networks and 4 platforms of expertise in clinical research.
It facilitates the development of skills and operational know-how in clinical research in France, serving both sponsors and investigators.
[Cliquez sur les images pour agrandir]
The PEDSTART network highlights the importance of the pediatric arm of the other F-CRIN, thematic networks, particularly in obesity (FORCE), the vaccines (I-Reivac), inflammatory diseases (CRI-IMMIDIATE) and severe asthma (CRISALIS).